Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 08:00 ET | Source: Channel Therapeutics Corporation

Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
May 01, 2025 17:00 ET | Source: Channel Therapeutics Corporation

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
December 20, 2024 09:00 ET | Source: Channel Therapeutics Corporation

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
December 18, 2024 08:30 ET | Source: Channel Therapeutics Corporation

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
November 21, 2024 09:49 ET | Source: Channel Therapeutics Corporation

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts ...
October 29, 2024 08:30 ET | Source: Chromocell Therapeutics Corporation

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
October 28, 2024 08:00 ET | Source: Chromocell Therapeutics Corporation

Chromocell to Present at Upcoming Fall Investor Conferences

FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
October 24, 2024 08:45 ET | Source: Chromocell Therapeutics Corporation

Chromocell Announces Amendment to Stock Repurchase Plan

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
September 03, 2024 09:00 ET | Source: Chromocell Therapeutics Corporation

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FREEHOLD, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
August 07, 2024 08:45 ET | Source: Chromocell Therapeutics Corporation

Chromocell Announces Stock Repurchase Plan

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...